TAGRISSO® (osimertinib) | AURA3 Study
Efficacy of TAGRISSO® (osimertinib) in resectable EGFRm NSCLC
Metastatic NSCLC Efficacy of TAGRISSO® (osimertinib)
PFS (A) and OS (B) in osimertinib and gefitinib treatment groups. *For... | Download Scientific Diagram
New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
TAGRISSO® (osimertinib) | FLAURA
TAGRISSO® (osimertinib) | AURA3 Study
TAGRISSO® (osimertinib) | AURA3 Study
Osimertinib in Advanced Lung Cancer with EGFR Mutations - National Cancer Institute
ADAURA Establishes Adjuvant Osimertinib as a New Standard of Care for Early-Stage EGFR-Mutated NSCLC
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy -
Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study | Future Oncology
TAGRISSO 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis - Annals of Oncology
Metastatic NSCLC Efficacy of TAGRISSO® (osimertinib)
Efficacy of TAGRISSO® (osimertinib) in resectable EGFRm NSCLC
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
TAGRISSO® (osimertinib) | FLAURA
TAGRISSO 40 mg film-coated tablets - Summary of Product Characteristics (SmPC) - print friendly - (emc)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
a) Overall survival from LM diagnosis for the total population. (b)... | Download Scientific Diagram
Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis | SpringerLink
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status - Journal of Thoracic Oncology
